WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H561495
CAS#: 26571-11-9
Description: Nonoxynol-9 is a human epidermal growth factor receptor-2 (HER2) inhibitor. It is also used as a surfactant and functions as a spermatocide.
Hodoodo Cat#: H561495
Name: Nonoxynol-9
CAS#: 26571-11-9
Chemical Formula: C33H60O10
Exact Mass: 616.42
Molecular Weight: 616.830
Elemental Analysis: C, 64.26; H, 9.80; O, 25.94
Synonym: Nonoxynol-9; Nonoxynol 9; Nonoxynol9; N9; N-9; N 9; Delfen; HSDB 8094; EINECS 247-816-5; Conceptrol;
IUPAC/Chemical Name: 2-[2-[2-[2-[2-[2-[2-[2-[2-(4-nonylphenoxy)ethoxy]ethoxy]ethoxy]ethoxy]-ethoxy]ethoxy]ethoxy]ethoxy]ethanol
InChi Key: FBWNMEQMRUMQSO-UHFFFAOYSA-N
InChi Code: InChI=1S/C33H60O10/c1-2-3-4-5-6-7-8-9-32-10-12-33(13-11-32)43-31-30-42-29-28-41-27-26-40-25-24-39-23-22-38-21-20-37-19-18-36-17-16-35-15-14-34/h10-13,34H,2-9,14-31H2,1H3
SMILES Code: CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1
Appearance: liquid
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 616.83 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Serfaty D. [Contraception during perimenopause: The spermicides option]. J Gynecol Obstet Hum Reprod. 2017 Mar;46(3):211-218. doi: 10.1016/j.jogoh.2016.10.007. Epub 2017 Jan 30. Review. French. PubMed PMID: 28403917.
2: Tanphaichitr N, Srakaew N, Alonzi R, Kiattiburut W, Kongmanas K, Zhi R, Li W, Baker M, Wang G, Hickling D. Potential Use of Antimicrobial Peptides as Vaginal Spermicides/Microbicides. Pharmaceuticals (Basel). 2016 Mar 11;9(1). pii: E13. doi: 10.3390/ph9010013. Review. PubMed PMID: 26978373; PubMed Central PMCID: PMC4812377.
3: Dewachter P, Mouton-Faivre C. [Allergy to iodinated drugs and to foods rich in iodine: Iodine is not the allergenic determinant]. Presse Med. 2015 Nov;44(11):1136-45. doi: 10.1016/j.lpm.2014.12.008. Epub 2015 Sep 19. Review. French. PubMed PMID: 26387623.
4: Krivorutchenko IuL, Andronovskaia IB. [Prospects of using miramistin for individual prevention of sexual HIV transmission]. Lik Sprava. 2013 Mar;(2):117-23. Review. Russian. PubMed PMID: 24605621.
5: Grimes DA, Lopez LM, Raymond EG, Halpern V, Nanda K, Schulz KF. Spermicide used alone for contraception. Cochrane Database Syst Rev. 2013 Dec 5;(12):CD005218. doi: 10.1002/14651858.CD005218.pub4. Review. PubMed PMID: 24307556.
6: Gupta SK, Nutan. Clinical use of vaginal or rectally applied microbicides in patients suffering from HIV/AIDS. HIV AIDS (Auckl). 2013 Oct 22;5:295-307. doi: 10.2147/HIV.S39164. Review. PubMed PMID: 24174883; PubMed Central PMCID: PMC3808211.
7: Grimes DA, Lopez LM, Raymond EG, Halpern V, Nanda K, Schulz KF. Spermicide used alone for contraception. Cochrane Database Syst Rev. 2013 Sep 30;(9):CD005218. doi: 10.1002/14651858.CD005218.pub3. Epub 2013 Sep 30. Review. Update in: Cochrane Database Syst Rev. 2013;(12):CD005218. PubMed PMID: 24085632.
8: Kuyoh MA, Toroitich-Ruto C, Grimes DA, Schulz KF, Gallo MF, Lopez LM. Sponge versus diaphragm for contraception. Cochrane Database Syst Rev. 2002 Jul 22;(5):CD003172. doi: 10.1002/14651858.CD003172. Review. PubMed PMID: 23866318.
9: Dukhin SS, Labib ME. Convective diffusion of nanoparticles from the epithelial barrier toward regional lymph nodes. Adv Colloid Interface Sci. 2013 Nov;199-200:23-43. doi: 10.1016/j.cis.2013.06.002. Epub 2013 Jun 10. Review. PubMed PMID: 23859221; PubMed Central PMCID: PMC3804055.
10: Friend DR, Kiser PF. Assessment of topical microbicides to prevent HIV-1 transmission: concepts, testing, lessons learned. Antiviral Res. 2013 Sep;99(3):391-400. doi: 10.1016/j.antiviral.2013.06.021. Epub 2013 Jul 8. Review. PubMed PMID: 23845918.
11: Driák D. [Sexually transmitted infections and spermicides]. Cas Lek Cesk. 2012;151(10):459-62. Review. Czech. PubMed PMID: 23256629.
12: Obiero J, Mwethera PG, Hussey GD, Wiysonge CS. Vaginal microbicides for reducing the risk of sexual acquisition of HIV infection in women: systematic review and meta-analysis. BMC Infect Dis. 2012 Nov 6;12:289. doi: 10.1186/1471-2334-12-289. Review. PubMed PMID: 23130761; PubMed Central PMCID: PMC3531270.
13: Obiero J, Mwethera PG, Wiysonge CS. Topical microbicides for prevention of sexually transmitted infections. Cochrane Database Syst Rev. 2012 Jun 13;(6):CD007961. doi: 10.1002/14651858.CD007961.pub2. Review. PubMed PMID: 22696373.
14: Adams JL, Kashuba AD. Formulation, pharmacokinetics and pharmacodynamics of topical microbicides. Best Pract Res Clin Obstet Gynaecol. 2012 Aug;26(4):451-62. doi: 10.1016/j.bpobgyn.2012.01.004. Epub 2012 Feb 4. Review. PubMed PMID: 22306523; PubMed Central PMCID: PMC3662244.
15: Gibson RM, Arts EJ. Past, present, and future of entry inhibitors as HIV microbicides. Curr HIV Res. 2012 Jan 1;10(1):19-26. Review. PubMed PMID: 22264042.
16: Stover KR, Riche DM, Gandy CL, Henderson H. What would we do without metronidazole? Am J Med Sci. 2012 Apr;343(4):316-9. doi: 10.1097/MAJ.0b013e3182254bd6. Review. PubMed PMID: 21817887.
17: Herold BC, Mesquita PM, Madan RP, Keller MJ. Female genital tract secretions and semen impact the development of microbicides for the prevention of HIV and other sexually transmitted infections. Am J Reprod Immunol. 2011 Mar;65(3):325-33. doi: 10.1111/j.1600-0897.2010.00932.x. Epub 2010 Dec 12. Review. PubMed PMID: 21143689; PubMed Central PMCID: PMC3058365.
18: Baptista M, Ramalho-Santos J. Spermicides, microbicides and antiviral agents: recent advances in the development of novel multi-functional compounds. Mini Rev Med Chem. 2009 Nov 1;9(13):1556-67. Review. PubMed PMID: 20205637.
19: Padian NS, McCoy SI, Balkus JE, Wasserheit JN. Weighing the gold in the gold standard: challenges in HIV prevention research. AIDS. 2010 Mar 13;24(5):621-35. doi: 10.1097/QAD.0b013e328337798a. Review. PubMed PMID: 20179575; PubMed Central PMCID: PMC3695696.
20: Batár I. State-of-the-art of non-hormonal methods of contraception: II. Chemical barrier contraceptives. Eur J Contracept Reprod Health Care. 2010 Apr;15(2):89-95. doi: 10.3109/13625180903462326. Review. PubMed PMID: 20055729.